Lanreotide

Lanreotide (CAS No.: 108736-35-2) is a synthetic peptide analog of somatostatin that is broadly classified as an endocrine and oncology research tool compound for investigating receptor mediated regulation of hormone secretion and proliferative signaling in neuroendocrine biology, with established relevance to growth hormone axis modulation and tumor associated secretory phenotypes in preclinical systems; mechanistically, it is studied primarily as an agonistic ligand for somatostatin receptor subtypes, especially SSTR2 and SSTR5, where receptor engagement is associated with inhibition of adenylyl cyclase activity, reduction of cyclic AMP dependent signaling, modulation of calcium flux, activation of phosphotyrosine phosphatase linked networks, and downstream attenuation of GH and IGF related signaling outputs that influence cell cycle progression, secretory behavior, and survival programs in selected cellular contexts; across published experimental literature and analog based pharmacology, functional activity is generally characterized within nanomolar to low micromolar concentration ranges depending on receptor expression density, assay format, and endpoint selection, and it is therefore commonly applied in receptor binding assays, second messenger profiling, endocrine secretion studies, neuroendocrine tumor cell line experiments, and translational pharmacology workflows that compare somatostatin pathway modulators in vitro and in vivo, including xenograft or other animal model paradigms designed to evaluate pathway engagement biomarkers rather than clinical efficacy, while concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.